PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Calcifediol→

Calcifediol PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
19356-17-3
Molecular formula
C27H44O2
Molecular weight
400.6 g/mol
Drug class
25-hydroxyvitamin D3vitamin D prohormone and precursor of calcitriol
Mechanism of action
Calcifediol (25-hydroxyvitamin D3) is converted in the kidney and other tissues to 1,25-dihydroxyvitamin D (calcitriol), which activates the vitamin D receptor and regulates calcium, phosphate and parathyroid hormone homeostasis.
Indications / reported uses
  • Treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency using the extended-release formulation; immediate-release products may have different vitamin D deficiency indications

Sources: US DailyMed — RAYALDEE (extended-release calcifediol) · NLM MeSH — Calcifediol · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Calcifediol PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Calcifediol Permitted Daily Exposure (PDE) report (the Calcifediol PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Calcifediol Occupational Exposure Limit (OEL) report (the Calcifediol OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.